Local Health Authority Roma 1, Department of Prevention, 00193 Rome, Italy.
Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy.
Nutrients. 2024 Apr 29;16(9):1345. doi: 10.3390/nu16091345.
This review aims to evaluate the efficacy of any vitamin administration(s) in preventing and managing COVID-19 and/or long-COVID. Databases were searched up to May 2023 to identify randomized clinical trials comparing data on the effects of vitamin supplementation(s) versus placebo or standard of care on the two conditions of interest. Inverse-variance random-effects meta-analyses were conducted to estimate pooled risk ratios (RRs) and 95% confidence intervals (CIs) for all-cause mortality between supplemented and non-supplemented individuals. Overall, 37 articles were included: two regarded COVID-19 and long-COVID prevention and 35 records the COVID-19 management. The effects of vitamin D in preventing COVID-19 and long-COVID were contrasting. Similarly, no conclusion could be drawn on the efficacy of multivitamins, vitamin A, and vitamin B in COVID-19 management. A few positive findings were reported in some vitamin C trials but results were inconsistent in most outcomes, excluding all-cause mortality (RR = 0.84; 95% CI: 0.72-0.97). Vitamin D results were mixed in most aspects, including mortality, in which benefits were observed in regular administrations only (RR = 0.67; 95% CI: 0.49-0.91). Despite some benefits, results were mostly contradictory. Variety in recruitment and treatment protocols might explain this heterogeneity. Better-designed studies are needed to clarify these vitamins' potential effects against SARS-CoV-2.
本综述旨在评估任何维生素制剂在预防和管理 COVID-19 和/或长新冠方面的疗效。检索数据库至 2023 年 5 月,以确定比较维生素补充剂与安慰剂或标准治疗对这两种关注疾病的效果的随机临床试验数据。采用逆方差随机效应荟萃分析估计补充组和非补充组之间全因死亡率的汇总风险比 (RR) 和 95%置信区间 (CI)。总体而言,纳入了 37 篇文章:其中 2 篇涉及 COVID-19 和长新冠的预防,35 篇记录了 COVID-19 的管理。维生素 D 在预防 COVID-19 和长新冠方面的效果相互矛盾。同样,对于多种维生素、维生素 A 和维生素 B 在 COVID-19 管理中的疗效,也无法得出结论。一些维生素 C 试验报告了一些阳性结果,但大多数结果不一致,排除全因死亡率(RR=0.84;95%CI:0.72-0.97)。维生素 D 的结果在大多数方面都存在差异,包括死亡率,只有常规给药才观察到益处(RR=0.67;95%CI:0.49-0.91)。尽管有一些益处,但结果大多相互矛盾。招募和治疗方案的差异可能解释了这种异质性。需要进行设计更好的研究来阐明这些维生素对 SARS-CoV-2 的潜在影响。